Education
About Us
Working with TipRanks
Follow Us
BioMark Diagnostics (TSE:BUX)
:BUX
BUX Stock Chart & Stats
C$0.46
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.46
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.20 - C$0.58
Previous CloseN/A
Volume0.00
Average Volume (3M)16.46K
Market Cap
C$55.70M
Enterprise ValueC$59.33M
Total Cash (Recent Filing)C$1.55M
Total Debt (Recent Filing)C$153.22K
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Mar 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding105,090,210
10 Day Avg. Volume19,330
30 Day Avg. Volume16,464
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)-41.95
Price to Sales (P/S)156.67
P/FCF Ratio-25.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageLow debt-to-equity (~0.18) gives BioMark structural financial flexibility: interest burden and mandatory repayments are limited, reducing insolvency risk. Over 2-6 months this supports funding of clinical validation and commercialization activities before major external financing is required.
Improving Free Cash Flow TrendAn improving free cash flow trend, even from negative levels, indicates early operational leverage and progress toward cash generation. Sustained improvement reduces reliance on dilutionary financings and supports continued investment in assay validation and commercialization over the medium term.
Specialized Diagnostics FocusA clear focus on blood-based cancer diagnostics targets a structural and growing market for early detection and monitoring. Proprietary biomarker discovery and assay development create differentiated capabilities and potential recurring revenues from clinical use if regulatory and commercial validation succeed.
Bears Say
Declining Revenue BaseA shrinking revenue base (-20.3% TTM) constrains the company's ability to scale fixed-cost investments in R&D, clinical validation, and commercial rollout. Without a durable reversal, continued top-line shrinkage undermines path to profitability and raises the probability of further financing needs.
Deeply Negative MarginsExtremely negative margins (~-1,340% net) reflect costs far outpacing revenue, eroding shareholder equity and reducing runway. Structural margin recovery will require material revenue scale or cost restructuring; absent that, losses will necessitate external capital and likely dilution.
Persistent Cash BurnSustained negative operating and free cash flow (roughly -$1.4M TTM) creates ongoing funding pressures. Even with low debt, persistent cash burn forces reliance on equity or other financing, constraining strategic flexibility and risking dilution that can impede long-term commercialization efforts.
BioMark Diagnostics News
BUX FAQ
What was BioMark Diagnostics’s price range in the past 12 months?
BioMark Diagnostics lowest stock price was C$0.20 and its highest was C$0.58 in the past 12 months.
What is BioMark Diagnostics’s market cap?
BioMark Diagnostics’s market cap is C$55.70M.
When is BioMark Diagnostics’s upcoming earnings report date?
BioMark Diagnostics’s upcoming earnings report date is Mar 03, 2026 which is in 10 days.
How were BioMark Diagnostics’s earnings last quarter?
BioMark Diagnostics released its earnings results on Nov 29, 2025. The company reported -C$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.005.
Is BioMark Diagnostics overvalued?
According to Wall Street analysts BioMark Diagnostics’s price is currently Overvalued.
Does BioMark Diagnostics pay dividends?
BioMark Diagnostics does not currently pay dividends.
What is BioMark Diagnostics’s EPS estimate?
BioMark Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioMark Diagnostics have?
BioMark Diagnostics has 105,090,210 shares outstanding.
What happened to BioMark Diagnostics’s price movement after its last earnings report?
BioMark Diagnostics reported an EPS of -C$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.448%.
Which hedge fund is a major shareholder of BioMark Diagnostics?
Currently, no hedge funds are holding shares in TSE:BUX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioMark Diagnostics
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
Technical Analysis
Spectral Medical
―
Telo Genomics Corp
―
StageZero Life Sciences Ltd
―
ZYUS Life Sciences
―
Sona Nanotech Inc
―
Options Prices
Currently, No data available
---